First National Bank Alaska announces unaudited results for fourth quarter and full year 2024 First National Bank Alaska's ...
Research and Development Expenses: Research and development expenses were $9.5 million for the full year 2024 compared to $4.7 million for the full year 2023. The increase of $4.8 million was ...
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback